PL2685995T3 - Kompozycje immunoterapeutyczne drożdże-Brachyury - Google Patents
Kompozycje immunoterapeutyczne drożdże-BrachyuryInfo
- Publication number
- PL2685995T3 PL2685995T3 PL12757534T PL12757534T PL2685995T3 PL 2685995 T3 PL2685995 T3 PL 2685995T3 PL 12757534 T PL12757534 T PL 12757534T PL 12757534 T PL12757534 T PL 12757534T PL 2685995 T3 PL2685995 T3 PL 2685995T3
- Authority
- PL
- Poland
- Prior art keywords
- yeast
- immunotherapeutic compositions
- brachyury immunotherapeutic
- brachyury
- compositions
- Prior art date
Links
- 230000001024 immunotherapeutic effect Effects 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/062—Ascomycota
- A61K36/064—Saccharomycetales, e.g. baker's yeast
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6006—Cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Oncology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Radiology & Medical Imaging (AREA)
- Pathology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Endocrinology (AREA)
- Pulmonology (AREA)
- Hematology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161453656P | 2011-03-17 | 2011-03-17 | |
| PCT/US2012/029636 WO2012125998A1 (en) | 2011-03-17 | 2012-03-19 | Yeast-brachyury immunotherapeutic compositions |
| EP12757534.8A EP2685995B1 (en) | 2011-03-17 | 2012-03-19 | Yeast-brachyury immunotherapeutic compositions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2685995T3 true PL2685995T3 (pl) | 2017-10-31 |
Family
ID=46831122
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL12757534T PL2685995T3 (pl) | 2011-03-17 | 2012-03-19 | Kompozycje immunoterapeutyczne drożdże-Brachyury |
Country Status (19)
| Country | Link |
|---|---|
| US (5) | US9198941B2 (enExample) |
| EP (2) | EP2685995B1 (enExample) |
| JP (4) | JP6068368B2 (enExample) |
| KR (1) | KR102046449B1 (enExample) |
| CN (1) | CN103648513B (enExample) |
| AU (3) | AU2012228937B2 (enExample) |
| BR (1) | BR112013023456B1 (enExample) |
| CA (1) | CA2835475C (enExample) |
| DK (1) | DK2685995T3 (enExample) |
| ES (1) | ES2627979T3 (enExample) |
| HK (1) | HK1245649A1 (enExample) |
| HU (1) | HUE033491T2 (enExample) |
| IL (1) | IL228421B (enExample) |
| MX (1) | MX350661B (enExample) |
| PL (1) | PL2685995T3 (enExample) |
| PT (1) | PT2685995T (enExample) |
| RU (2) | RU2690180C2 (enExample) |
| SG (2) | SG193396A1 (enExample) |
| WO (1) | WO2012125998A1 (enExample) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2725450T3 (es) | 2007-07-02 | 2019-09-24 | Etubics Corp | Métodos y composiciones para la producción de un vector adenoviral para su uso en vacunaciones múltiples |
| EP2651439B1 (en) | 2010-12-17 | 2018-09-19 | Globeimmune, Inc. | Compositions and methods for the treatment or prevention of human adenovirus-36 infection |
| PE20140844A1 (es) | 2011-02-12 | 2014-07-14 | Globeimmune Inc | Terapeuticos a base de levadura para infeccion de la hepatitis b cronica |
| JP6068368B2 (ja) | 2011-03-17 | 2017-01-25 | グローブイミューン，インコーポレイテッド | 酵母−ブラキュリ免疫治療組成物 |
| EP2720716B1 (en) | 2011-06-14 | 2018-03-21 | Globeimmune, Inc. | Immunotherapeutic compositions for the treatment or prevention of hepatitis delta virus infection |
| CN109010809A (zh) | 2011-08-17 | 2018-12-18 | 全球免疫股份有限公司 | 酵母-muc1免疫治疗组合物及其用途 |
| KR102103319B1 (ko) | 2012-06-26 | 2020-04-22 | 바이오디식스, 인크. | 면역반응 발생 요법으로 치료하기 위해 암환자들의 선택, 및 선택해제를 위한 질량-스펙트럼법 |
| US9605276B2 (en) | 2012-08-24 | 2017-03-28 | Etubics Corporation | Replication defective adenovirus vector in vaccination |
| WO2014043518A1 (en) | 2012-09-14 | 2014-03-20 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Brachyury protein, non-poxvirus non-yeast vectors encoding brachyury protein, and their use |
| MX374829B (es) * | 2013-03-19 | 2025-03-06 | Globeimmune Inc | Composición a base de levadura para usarse para tratar cordoma. |
| US9782473B2 (en) | 2013-03-26 | 2017-10-10 | Globeimmune, Inc. | Compositions and methods for the treatment or prevention of human immunodeficiency virus infection |
| US9725494B2 (en) * | 2013-05-17 | 2017-08-08 | United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Soluble CD27 (sCD27) and the use thereof |
| TWI654200B (zh) | 2013-08-30 | 2019-03-21 | 環球免疫公司 | 治療或預防結核病的組合物及方法 |
| CA2948803A1 (en) | 2014-04-11 | 2015-10-15 | Globeimmune, Inc. | Yeast-based immunotherapy and type i interferon sensitivity |
| AU2016205215B2 (en) | 2015-01-09 | 2021-03-11 | Etubics Corporation | Methods and compositions for combination immunotherapy |
| US11149087B2 (en) | 2015-04-20 | 2021-10-19 | Etubics Corporation | Methods and compositions for combination immunotherapy |
| TWI748957B (zh) * | 2015-08-03 | 2021-12-11 | 美商環球免疫公司 | 經修飾之酵母-短尾畸型（Ｂｒａｃｈｙｕｒｙ）免疫治療組合物 |
| JP7048482B2 (ja) | 2015-08-03 | 2022-04-05 | アメリカ合衆国 | Ｂｒａｃｈｙｕｒｙ欠失変異体、Ｂｒａｃｈｙｕｒｙ欠失変異体をコードする非酵母ベクター、及びそれらの使用 |
| JP2019513021A (ja) | 2016-03-24 | 2019-05-23 | ナントセル，インコーポレイテッド | ネオエピトープ提示のための配列の配置および配列 |
| US20190125852A1 (en) * | 2016-06-03 | 2019-05-02 | Etubics Corporation | Compositions and methods for tumor vaccination using prostate cancer-associated antigens |
| WO2018094190A2 (en) * | 2016-11-18 | 2018-05-24 | Sanford Burnham Prebys Medical Discovery Institute | Gut microbiota and treatment of cancer |
| CA3061240C (en) | 2017-04-24 | 2024-01-16 | Nantcell, Inc. | Targeted neoepitope vectors and methods therefor |
| US11510982B2 (en) * | 2017-08-15 | 2022-11-29 | Nantcell, Inc. | HaNK cetuximab combinations and methods |
| CN119818663A (zh) | 2018-05-15 | 2025-04-15 | 全球免疫公司 | 用于诱导细胞免疫应答的重组酵母裂解物 |
| US12285480B2 (en) | 2020-03-11 | 2025-04-29 | Nantcell, Inc. | Method of inducing immunity against SARS-CoV-2 using spike and nucleocapsid-ETSD immunogens delivered by RNA and replication-defective adenoviruses |
| US11857620B2 (en) | 2020-03-11 | 2024-01-02 | Immunitybio, Inc. | Method of inducing immunity against SARS-CoV-2 using spike (s) and nucleocapsid (N)-ETSD immunogens delivered by a replication-defective adenovirus |
| US20210284716A1 (en) | 2020-03-11 | 2021-09-16 | Immunitybio, Inc. | ACE2-Fc Trap |
| US12245355B2 (en) | 2021-02-19 | 2025-03-04 | Mevion Medical Systems, Inc. | Gantry for a particle therapy system |
| EP4489774A4 (en) * | 2022-03-08 | 2026-04-29 | Immunitybio Inc | YEAST-BASED VACCINE INJECTED INTRATUMORALLY |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1036329A (en) | 1908-11-19 | 1912-08-20 | Edison Inc Thomas A | Phonograph-reproducer. |
| FR2486400B1 (fr) | 1980-07-09 | 1986-05-30 | Univablot | Medicaments a base de levures ou de leurs extraits insolubles |
| NZ199722A (en) | 1981-02-25 | 1985-12-13 | Genentech Inc | Dna transfer vector for expression of exogenous polypeptide in yeast;transformed yeast strain |
| US4775622A (en) | 1982-03-08 | 1988-10-04 | Genentech, Inc. | Expression, processing and secretion of heterologous protein by yeast |
| US5310654A (en) | 1985-07-31 | 1994-05-10 | The Board Of Trustees Of The Leland Stanford Junior University | Method for determining virulence of Yersinia |
| US5234830A (en) | 1988-02-03 | 1993-08-10 | Suntory Limited | DNA encoding a KEX2 endoprotease without a C-terminal hydrophobic region |
| IL95019A0 (en) | 1989-08-09 | 1991-06-10 | Mycogen Corp | Process for encapsulation of biologicals |
| US5830463A (en) | 1993-07-07 | 1998-11-03 | University Technology Corporation | Yeast-based delivery vehicles |
| US5413914A (en) | 1993-07-07 | 1995-05-09 | The Regents Of The University Of Colorado | Yeast assay to identify inhibitors of dibasic amino acid processing endoproteases |
| US5858378A (en) | 1996-05-02 | 1999-01-12 | Galagen, Inc. | Pharmaceutical composition comprising cryptosporidium parvum oocysts antigen and whole cell candida species antigen |
| US20020044948A1 (en) | 2000-03-15 | 2002-04-18 | Samir Khleif | Methods and compositions for co-stimulation of immunological responses to peptide antigens |
| EP1272213B1 (en) | 2000-04-06 | 2006-03-08 | SEER Pharmaceuticals, LLC. | Microbial delivery system |
| AU2002225681A1 (en) | 2000-11-15 | 2002-05-27 | Globe Immune, Inc. | Yeast-dentritic cell vaccines and uses thereof |
| JP4914990B2 (ja) | 2002-12-16 | 2012-04-11 | グローブイミューン，インコーポレイテッド | 動物を癌から守るための治療用組成物 |
| US7439042B2 (en) | 2002-12-16 | 2008-10-21 | Globeimmune, Inc. | Yeast-based therapeutic for chronic hepatitis C infection |
| WO2007008780A2 (en) | 2005-07-11 | 2007-01-18 | Globeimmune, Inc. | Compositions and methods for eliciting an immune response to escape mutants of targeted therapies |
| US20070172503A1 (en) | 2005-12-13 | 2007-07-26 | Mycologics,Inc. | Compositions and Methods to Elicit Immune Responses Against Pathogenic Organisms Using Yeast Based Vaccines |
| CA2638815A1 (en) * | 2006-02-02 | 2007-08-16 | Globeimmune, Inc. | Yeast-based vaccine for inducing an immune response |
| TW200806789A (en) * | 2006-03-27 | 2008-02-01 | Globeimmune Inc | RAS mutation and compositions and methods related thereto |
| CN101687030B (zh) | 2007-02-02 | 2014-07-02 | 环球免疫公司 | 用于生产基于酵母的疫苗的方法 |
| CA2678404C (en) * | 2007-02-28 | 2019-03-19 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Brachyury polypeptides and methods for use |
| WO2008115610A1 (en) | 2007-03-19 | 2008-09-25 | Globeimmune, Inc. | Compositions and methods for targeted ablation of mutational escape of targeted therapies for cancer |
| WO2009042642A2 (en) | 2007-09-24 | 2009-04-02 | President And Fellows Of Harvard College | Compositions and methods for the treatment and prevention of ulcerative colitis and colon cancer |
| EP2331125A4 (en) | 2008-09-19 | 2013-03-27 | Globeimmune Inc | IMMUNOTHERAPY FOR CHRONIC HEPATITIS C-VIRUS INFECTIONS |
| WO2010065626A1 (en) | 2008-12-02 | 2010-06-10 | Globeimmune, Inc. | Genotyping tools, methods and kits |
| ES2660597T3 (es) * | 2009-04-17 | 2018-03-23 | Globeimmune, Inc. | Composiciones inmunoterápicas de combinación contra el cáncer y métodos |
| US8911722B2 (en) | 2009-09-14 | 2014-12-16 | The Regents Of The University Of Colorado, A Body Corporate | Modulation of yeast-based immunotherapy products and responses |
| US20130121964A1 (en) | 2010-03-14 | 2013-05-16 | Globeimmune, Inc. | Pharmacogenomic and Response-Guided Treatment of Infectious Disease Using Yeast-Based Immunotherapy |
| WO2012019127A2 (en) * | 2010-08-05 | 2012-02-09 | The Regents Of The University Of Colorado | Combination yeast-based immunotherapy and arginine therapy for the treatment of myeloid-derived supressor cell-associated diseases |
| EP2651439B1 (en) | 2010-12-17 | 2018-09-19 | Globeimmune, Inc. | Compositions and methods for the treatment or prevention of human adenovirus-36 infection |
| PE20140844A1 (es) | 2011-02-12 | 2014-07-14 | Globeimmune Inc | Terapeuticos a base de levadura para infeccion de la hepatitis b cronica |
| JP6068368B2 (ja) | 2011-03-17 | 2017-01-25 | グローブイミューン，インコーポレイテッド | 酵母−ブラキュリ免疫治療組成物 |
| EP2720716B1 (en) | 2011-06-14 | 2018-03-21 | Globeimmune, Inc. | Immunotherapeutic compositions for the treatment or prevention of hepatitis delta virus infection |
| CN109010809A (zh) | 2011-08-17 | 2018-12-18 | 全球免疫股份有限公司 | 酵母-muc1免疫治疗组合物及其用途 |
-
2012
- 2012-03-19 JP JP2013558234A patent/JP6068368B2/ja active Active
- 2012-03-19 CA CA2835475A patent/CA2835475C/en active Active
- 2012-03-19 HU HUE12757534A patent/HUE033491T2/en unknown
- 2012-03-19 PT PT127575348T patent/PT2685995T/pt unknown
- 2012-03-19 KR KR1020137027169A patent/KR102046449B1/ko active Active
- 2012-03-19 ES ES12757534.8T patent/ES2627979T3/es active Active
- 2012-03-19 SG SG2013068176A patent/SG193396A1/en unknown
- 2012-03-19 DK DK12757534.8T patent/DK2685995T3/en active
- 2012-03-19 WO PCT/US2012/029636 patent/WO2012125998A1/en not_active Ceased
- 2012-03-19 MX MX2013010475A patent/MX350661B/es active IP Right Grant
- 2012-03-19 RU RU2017116350A patent/RU2690180C2/ru active
- 2012-03-19 EP EP12757534.8A patent/EP2685995B1/en active Active
- 2012-03-19 AU AU2012228937A patent/AU2012228937B2/en active Active
- 2012-03-19 BR BR112013023456-3A patent/BR112013023456B1/pt active IP Right Grant
- 2012-03-19 EP EP17154014.9A patent/EP3238731B1/en active Active
- 2012-03-19 SG SG10201601913RA patent/SG10201601913RA/en unknown
- 2012-03-19 RU RU2013146324A patent/RU2619850C2/ru active IP Right Revival
- 2012-03-19 PL PL12757534T patent/PL2685995T3/pl unknown
- 2012-03-19 CN CN201280023412.6A patent/CN103648513B/zh active Active
-
2013
- 2013-03-14 US US13/803,719 patent/US9198941B2/en active Active
- 2013-09-12 IL IL228421A patent/IL228421B/en active IP Right Grant
-
2015
- 2015-10-29 US US14/926,372 patent/US9623097B2/en active Active
-
2016
- 2016-12-22 JP JP2016249307A patent/JP6309607B2/ja active Active
-
2017
- 2017-02-02 AU AU2017200715A patent/AU2017200715B2/en active Active
- 2017-03-09 US US15/454,176 patent/US10363294B2/en active Active
-
2018
- 2018-03-14 JP JP2018046148A patent/JP6580733B2/ja active Active
- 2018-04-19 HK HK18105126.6A patent/HK1245649A1/en unknown
- 2018-04-30 AU AU2018202972A patent/AU2018202972B2/en active Active
-
2019
- 2019-04-19 US US16/389,235 patent/US11944673B2/en active Active
- 2019-08-28 JP JP2019155138A patent/JP2019199484A/ja active Pending
-
2020
- 2020-12-21 US US17/129,633 patent/US11938175B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| LTPA2018516I1 (lt) | Testosterono kompozicijos | |
| LT2791160T (lt) | Modifikuotos mrnr sudėtys | |
| IL232053B (en) | Antibody formulations | |
| LT2742151T (lt) | Polimerazės kompozicija | |
| BR112013022112A2 (pt) | composição | |
| BR112013017183A2 (pt) | composições de bepostatina | |
| DK2686017T3 (da) | Oftalmisk sammensætning | |
| BR112014004395A2 (pt) | composição | |
| CO6980663A2 (es) | Composiciones fungicidas | |
| IL228421A0 (en) | Immunotherapeutic compositions against yeast brachyury protein | |
| DK2640893T4 (da) | Sammensætninger | |
| LT3246021T (lt) | Apiksabano kompozicijos | |
| EP2706981A4 (en) | COSMETIC COMPOSITIONS | |
| EP2726548A4 (en) | HARDENING COMPOSITIONS | |
| LT3725778T (lt) | Enzalutamido kompozicijos | |
| EP2721111A4 (en) | HEAT-RELATED THERMOPLASTIC COMPOSITIONS | |
| CO6930368A2 (es) | Composiciones de yodo-povidona estable | |
| CO6910197A2 (es) | Compuestos novedosos | |
| ME03413B (me) | Kompozicije које sadrže peg i askorbat | |
| BR112013033808A2 (pt) | composição | |
| LT3272861T (lt) | Alfa-galaktozidazės kompozicijos | |
| LT2729012T (lt) | Pieno pagrindo kompozicijos | |
| FI11374U1 (fi) | Bensiinikoostumukset | |
| EP2730619A4 (en) | COMPOSITION | |
| PT2739276T (pt) | Composição antisséptica |